1. Background {#sec128198}
=============

Chronic hepatitis B (HB) infection is endemic in Malaysia and throughout South-East Asia. Chronic HB infection manifestation is diverse ranged from an inactive carrier status to advance stage, which may progress to cirrhosis and hepatocellular carcinoma (HCC). Chronic HB is present as either hepatitis B e antigen (HBeAg)-positive or HBeAg-negative. HBeAg is a viral protein secreted by HBV infected cells. HBeAg is thought to be an indicator of viral replication and to predict patient\'s degree of infectiousness, whereas presence of anti-HBe antibodies often indicates a low level of viral replication ([@A31490R1]). The presence of HBeAg is pivotal in deciding treatment whereby oral antiviral medication is continued until HBeAg seroconversion is achieved ([@A31490R2]).

HBV has high tendency to acquire mutations in different regions of its genome including polymerase, surface antigen, core/pre-core promoter and X gene regions. Our previous studies in Malaysia have shown drug resistance mutations in polymerase gene and S gene mutations of HBV ([@A31490R3], [@A31490R4]). Further interest to investigate mutations present in the pre-core region of the virus is mainly due to the association of these mutations with development of HBeAg-negative phenotype.

A predominant mutation in the pre-core region involves a G to A change at nucleotide1896 (G1896A), which generates a premature stop codon at codon 28 ([@A31490R5]). This mutation has crucial role in preventing translation of HBeAg and completely hampers the production of HBeAg antigen. Thus, emergence of stop codon mutation may be a means of immune evasion. In addition, a double mutation at nucleotides 1762/1764 at the core promoter region was observed to affect HBeAg production ([@A31490R6]).

2. Objectives {#sec128199}
=============

The aim of this study was to identify the presence of G1896A mutant in HBV virus isolated from Malaysian HBV carriers and determine the association of this mutation with several parameters such as clinical status, genotype and HBeAg status.

3. Patients and Methods {#sec128205}
=======================

3.1. Ethics Statement {#sec128200}
---------------------

This study obtained ethical approval from Ethics and medical research committee, ministry of health Malaysia (Reference number: NMRR-12-311-11789). The ethics committee indicated that patient consent was not required as the samples used were retrospective and confirmed as Hepatitis B carriers.

3.2. Serum Samples {#sec128201}
------------------

The study included 93 retrospective blood serum samples of confirmed Hepatitis B carriers, obtained from Hospital Selayang, Kuala Lumpur, Malaysia. The samples were collected randomly regardless of age, race, sex, treatment and symptoms for a period of three years (2012 - 2014). Demographic data of patients involved in this study are indicated in [Table 1](#tbl33168){ref-type="table"}.

###### Demographic Data of Patients Involved in the Present Study^[a](#fn34746){ref-type="table-fn"}^

  Variables                     Groups                 
  ----------------------------- ---------------------- ----------------------
  **Age, y**                    52.3 ± 16.3            48.3 ± 16.8
  **Gender (Male:Female)**      13:11                  48:21
  **HBV DNA copy, IU/mL**       1.24×107 ± 3.39 ×107   1.16 ×105 ± 2.53×105
  **Normal ALT level**          87.5                   70.0
  **Elevated ALT level**        12.5                   30.0
  **HBeAg-negative**            21 (87.5)              48 (69.6)
  **HbeAg-positive**            3 (12.5)               21 (30.4)
  **HCC**                       2 (8.3)                11 (15.9)
  **Liver cirrhosis**           10 (41.7)              9 (13.0)
  **Asymptomatic CHB**          14 (58.3)              45 (65.2)
  **Fulminant Hepatitis B**     1 (4.2)                0 (0)
  **Acute Hepatitis B Flare**   0 (0)                  3 (4.3)
  **e-seroconversion**          2 (8.3)                2 (2.9)

^a^Data are presented as mean ± SD, percent or No. (%).

3.3. HBV DNA Extraction and Amplification {#sec128202}
-----------------------------------------

HBV DNA was extracted from serum samples using High Pure Viral Nucleic Acid Extraction Kit (Roche, USA) according to the manufacturer's instructions. The 3.215 kb length HBV full genome was amplified using 14 sets of oligonucleotides published previously. PCR amplification using primers published by Sugauchi et al. (2001) ([@A31490R7]) was performed by nested PCR, whereas amplification with primers published by Kahila Bar-Gal et al. (2012) ([@A31490R8]) performed by direct PCR. All PCR conditions were performed as described by Suppiah et al. (2014) ([@A31490R4]).

3.4. Sequencing {#sec128203}
---------------

A 15 uL aliquot of each PCR reaction was analyzed on 2% prestained agarose by gel electrophoresis and viewed under UV illumination. The amplicons were extracted from agarose gel and purified using gel extraction kit (Qiagen, USA) according to the manufacturer's instruction. All purified PCR amplicons were subjected to cycle sequencing using corresponding sense and antisense oligonucleotides and sequenced in 3730 genetic analyzer (Applied Biosystem, USA) using standard sequencing protocol.

3.5. Data Analysis {#sec128204}
------------------

The full genome of HBV was obtained by aligning overlapping sense and antisense sequences using CLUSTAL Omega tool (https://www.ebi.ac.uk/Tools/msa/clustalo/). The reference sequence used in the alignment was Hepatitis B virus isolate M1 (GenBank Accession number: GQ924603). The genotypes of Malaysian Hepatitis B carriers were determined by Genotyper bioinformatics tool and phylogenetic analysis (data published). The consensus sequences were then analyzed at the basal core promoter (BCP), precore (PC) and core (C) region and particularly observed for presence of G1986A mutation. Association of G1986A with few parameters such as HBeAg status, genotype, liver diseases and e-seroconversion rate were statistically determined by chi-square analysis.

4. Results {#sec128213}
==========

4.1. HBV Full Genome Sequencing and Genotyping {#sec128206}
----------------------------------------------

A total 76 HBV complete nucleotide and 17 partial nucleotide sequences were obtained by PCR amplification and sequencing. (GenBank Accession numbers: KJ803752-KJ803827). Genotyping of the full genome sequences by HEPSEQ software revealed a distribution of 49.46%, 48.39% and 2.15% of genotypes C, B, and D, respectively; whereas, phylogenetic and jumping profile Hidden Markov Model (jpHMM) analysis identified six (7.89%) recombinant B/C strains (published result) ([@A31490R4]).

4.2. BCP, PC and C Region Analysis {#sec128207}
----------------------------------

The most commonly observed mutation in the precore region was C1858T, which comprised 64.5% of all isolates sequenced. The precore mutation of interest (G1896A) was identified in 25.8% of isolates. Among the basal core promoter mutations, A1762T-G1764A double mutation was present in 26.9%, C1653T in 8.6%, A1752G in1 0.8% and C1766T in 2.2% of all isolates. Circulation of genotypes among these mutations is summarized in [Table 2](#tbl33169){ref-type="table"}.

###### Distribution of HBV Genotypes With Pre-core and Core Promoter Mutations Among Malaysian Subjects^[a](#fn34747){ref-type="table-fn"}^

  Genotypes   Precore Mutations   Basal Core Promoter Mutations                   
  ----------- ------------------- ------------------------------- ---- ----- ---- ----
  **B**       67                  48                              24   0     80   50
  **C**       29                  45                              64   100   0    50
  **B/C**     0                   3                               8    0     20   0
  **D**       4                   3                               4    0     0    0

^a^Data are presented as percent.

4.3. G1896 A Mutation in Relation to HBeAg Status {#sec128208}
-------------------------------------------------

From 93 subjects, 69 were HBeAg-negative and 24 HBeAg positive. Precore stop codon G1896A was detected in 30.4% (21/69) of HBeAg-negative subjects and 12.5% (3/24) of HBeAg-positive cases. In total, there were 24 hepatitis B infected subjects with G1896A mutant, of whom all were HBeAg-negative except three. The mutation was more prevalent in HBeAg-negative than HBeAg-positive subjects, nevertheless the difference was not statistically significant (P \> 0.05).

4.4. Genotype and Association With G1896A Mutation {#sec128209}
--------------------------------------------------

Malaysian HBV isolates were clustered into genotypes C, B, recombinant B/C and D with a frequency of 47.37%, 43.42%, 7.89% and 1.32%, respectively ([@A31490R4]). It was observed that the prevalence of HBV infected subjects with G1896A mutation in genotypes B and C was comparable. The occurrence of mutation in genotype B group was 48.5% (16/33) and in genotype C group was 19.4% (7/36). Similarly, within the mutation group, genotype B was the most prevalent genotype (67%). The precore stop codon mutation was not present in any of the recombinant B/C genotype and there was one genotype D subject who carried the mutation. Chi-square analysis revealed a significant association between HBV genotype and G1896A mutation, whereby subjects infected with HBV genotype B had G1896A mutation more commonly (P \< 0.05).

4.5. G1896A Mutation in Relation to Clinical Status of Subjects {#sec128210}
---------------------------------------------------------------

Clinical status of patients categorized into asymptomatic chronic HB, liver cirrhosis, fulminant hepatitis, hepatocellular carcinoma (HCC) and acute HB flare ([Table 1](#tbl33168){ref-type="table"}). Subjects with G1896A mutations were mainly in asymptomatic chronic HB (58.3%) and liver cirrhosis (41.7%) groups. Fulminant hepatitis was diagnosed in one patient (4.2%) and 8.3% had HCC. There was a significant association between G1896A occurrence in subjects and liver cirrhosis (P \< 0.05). Though the number of subjects with fulminant hepatitis is extremely low, the only subject in the study carried the mutation. Two subjects infected with HBV and had G1896A mutation diagnosed with HCC. However, there was no statistical association between HCC and G1896A.

4.6. G1896A Mutation and e-Seroconversion {#sec128211}
-----------------------------------------

Three of 24 subjects with G1896A were HBeAg-positive. Among the three, two had e-seroconversion. Both subjects were male, aged 37 and 40 and diagnosed with chronic HB. Similarly, in non-mutant group, two more subjects had e-seroconversion. The electropherogram showed a heterozygous peak in the forward sequence for the two subjects with e-seroconversion. This was not observed in the subject without seroconversion where both forward and reverse sequences showed homozygous mutant peak.

4.7. Prevalence of G1896A Mutation in Comparison to Age and Genotypes {#sec128212}
---------------------------------------------------------------------

Age comparison among HBV patients harboring G1896A revealed that, in all 3 genotypes (B, C and D), middle-aged adults (36 - 55 years old) had prominent distribution of the mutation (41.7%, 12.5% and 4.2%), respectively. The stop codon mutation was equally observed in the geriatrics group belonging to genotypes B and C and none were found in the pediatrics group ([Table 3](#tbl33170){ref-type="table"}).

###### Prevalence of G1896A Mutation Among Different Age Groups and Genotypes

  Genotypes   Paediatric (0 - 17)   Adult (18 - 65)   Geriatrics (≥ 66)          
  ----------- --------------------- ----------------- ------------------- ------ -----
  **B**       0                     4.2               41.7                16.7   4.2
  **C**       0                     4.2               12.5                8.3    4.2
  **B/C**     0                     0                 0                   0      0
  **D**       0                     0                 4.2                 0      0

5. Discussion {#sec128214}
=============

Precore mutants of HBV caused infections difficult to treat, prolonged duration and higher risk of liver cirrhosis. These mutations include a change in DNA bases from guanine to adenine at position 1896 (G1896A), and from cytosine to thymine at position 1858 (C1858T) of the viral genome. From the analysis of the Malaysian HBV sequences, most isolates were found to confer C1858T mutation in the precore region. This finding is in agreement with reports of T1858 variant commonly found in Asian regions ([@A31490R9], [@A31490R10]).

Genotype predominance was not observed in subjects with C1858T mutation as it was equally distributed among HBV B and C genotypes and found in two of the D genotype. Other studies found major existence up to 100% of T1858 variant in genotypes B, D and E, moderately or heterogeneously in genotype C and less common in genotype A ([@A31490R11]-[@A31490R13]). The mutation of interest G1896A was also present in HBV sequences. Interestingly, it was observed that all subjects with A1896 variant carried the T1858 variant. The T1858 substitution is known to be a provocateur of A1896 mutation that abolishes synthesis of HBeAg ([@A31490R14]). G1896A mutation is located within the epsilon (ε) structure, a highly conserved stem-loop essential for the initiation of encapsidation during viral replication ([@A31490R15]). When G1986A mutation is paired with C1858T, the ε structure is more stabilized, thus enhancing viral replication. Therefore, development of G1896A mutation relies on the presence or absence of C or T at position 1858, which is genotype dependent ([@A31490R1], [@A31490R16]).

Our findings suggested that G1896A mutation was not significantly associated with HBeAg-negativity. This is contradicted by several studies reporting that A1896 variant existence is profound in HBeAg-negative subjects ([@A31490R1], [@A31490R17], [@A31490R18]). On the other hand, when HBeAg status was compared within the subjects that had A1896 mutation, a large proportion were HBeAg-negative (21/24, 87.5%). However, when statistically determined, this association was insignificant as a large number of HBeAg-negative status was observed in the non-mutant group. Generally, a very low prevalence (0% - 9.3%) of A1896 variant in HBV has been observed in Malaysia since late 1990's and early 2000's ([@A31490R11], [@A31490R19], [@A31490R20]). Furthermore, absence of HBeAg in HBV infected patients does not necessarily indicate the presence of pre-core mutant entirely.

The G1896A mutation was more prevalent in HBV genotype B than genotype C in Malaysia. In accordance to the finding of this study, few other countries such as Indonesia, Vietnam and East Asia reported a significant association between genotype B and G1896A mutation ([@A31490R13], [@A31490R21], [@A31490R22]). The basis behind genotype selectivity of G1896A mutant mainly points to the C1898T mutation, which is prominently present in genotypes B, D and E.

Regarding the relation of G1896A mutation and clinical status of study subjects, it was observed that the stop codon mutation was significantly present in patients with asymptomatic chronic hepatitis B and liver cirrhosis. The proportion of patients with liver cirrhosis who acquired A1896 variant in our study (41.7%) is similar to the findings by Tong et al. ([@A31490R23]) (42.0%). However, the same study found a strong correlation of mutation with development of HCC, which was not observed in our study. There was one subject in the present study with fulminant hepatitis who had G1896A mutation. Association could not be drawn from this finding as the number of fulminant hepatitis in this study was limited to one. However, there have been numerous reports describing an association between precore stop codon mutation and fulminant hepatitis ([@A31490R24]-[@A31490R26]). G1896A was thought to cause severe liver disease as it is frequently found in patients with chronic hepatitis B, liver cirrhosis and fulminant hepatitis. Conversely, several studies detected this mutation in asymptomatic HBV carriers ([@A31490R27], [@A31490R28]). Thus, the role of this mutation in triggering severe form of hepatitis is unclear.

The role of G1896A mutation in HBeAg-positive seroconversion has been reported ([@A31490R29]). In the present study, from 5 subjects with e-seroconversion, two conferred G1896A mutation. Similarity in age, gender and clinical status was observed in both patients. However, it is unclear if this mutation occurred before or after e-seroconversion. This is because retrospective samples were used in this study; therefore, no follow-up was performed for subjects. However, heterozygous A1896 and G1896 peak observed in only one sequence direction may suggest the role of G1896A in triggering e-seroconversion.

The present study also evidenced prominent prevalence of G1896A mutation among middle-aged adult group followed by older adult group and low prevalence in geriatric and pediatric groups. This finding is supported by another study that showed a high prevalence of this mutation among middle-aged patients ([@A31490R30]). The reason for selectivity of stop codon mutation in middle-aged group is unclear. The absence of stop codon mutation among pediatric group was inconclusive as only one subject from the mentioned group was available for this study.

In conclusion, the study findings showed an intermediate prevalence of G1896A mutation among Malaysian hepatitis B carriers. No significant association was observed between G1896A mutations and its role in causing HBeAg-negativity. However, our data suggested a significant association of G1896A with genotype B and patients with chronic hepatitis B and liver cirrhosis.
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